汤臣倍健(300146)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300146 汤臣倍健

已收盘 03-02 15:00:00

{"stockData":{"symbol":"300146","market":"SZ","secType":"STK","nameCN":"汤臣倍健","latestPrice":11.82,"timestamp":1772435004000,"preClose":12.06,"halted":0,"volume":22524248,"delay":0,"changeRate":-0.0199,"floatShares":1121000000,"shares":1692000000,"eps":0.4088,"marketStatus":"已收盘","change":-0.24,"latestTime":"03-02 15:00:00","open":11.95,"high":12.03,"low":11.73,"amount":267000000,"amplitude":0.0249,"askPrice":11.83,"askSize":70,"bidPrice":11.82,"bidSize":212,"shortable":0,"etf":0,"ttmEps":0.4088,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772501400000},"marketStatusCode":5,"adr":0,"adjPreClose":12.06,"symbolType":"stock","openAndCloseTimeList":[[1772415000000,1772422200000],[1772427600000,1772434800000]],"highLimit":13.27,"lowLimit":10.85,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1691677031,"isCdr":false,"pbRate":1.8,"roa":"--","peRate":28.913894,"roe":"8.12%","epsLYR":0.39,"committee":0.655752,"marketValue":19996000000,"turnoverRate":0.0201,"status":1,"floatMarketCap":13248000000},"requestUrl":"/m/hq/s/300146","defaultTab":"news","newsList":[{"id":"2616352405","title":"股市必读：汤臣倍健（300146）3月2日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2616352405","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616352405?lang=zh_cn&edition=full","pubTime":"2026-03-03 01:17","pubTimestamp":1772471828,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘，汤臣倍健报收于11.82元，下跌1.99%，换手率2.01%，成交量22.52万手，成交额2.67亿元。董秘最新回复投资者： 请问公司是否有美白类护肤类的产品。公司主营膳食营养补充剂业务，旗下拥有保健功能为“有助于抗氧化”“有助于改善皮肤水分状况”的产品。国家市场监督管理总局目前尚未将“美白”单独列为可声称的保健功能。交易信息汇总资金流向3月2日主力资金净流出2440.01万元；游资资金净流入2284.63万元；散户资金净流入155.38万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300000702.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0146","300146","BK0226","BK0114","BK0042","BK0028","BK0107"],"gpt_icon":0},{"id":"2616387557","title":"汤臣倍健：旗下拥有保健功能为“有助于抗氧化”“有助于改善皮肤水分状况”的产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2616387557","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616387557?lang=zh_cn&edition=full","pubTime":"2026-03-02 17:24","pubTimestamp":1772443459,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)03月02日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司是否有美白类护肤类的产品。有无进军化口福妆品领域的计划？汤臣倍健回复：投资者您好！公司主营膳食营养补充剂业务，旗下拥有保健功能为“有助于抗氧化”“有助于改善皮肤水分状况”的产品。国家市场监督管理总局目前尚未将“美白”单独列为可声称的保健功能。感谢关注。为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260302/32037934.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0028","BK0226","BK0146","BK0114","BK0107","300146","BK0042"],"gpt_icon":0},{"id":"2614814816","title":"汤臣倍健：行业相关法规的陆续完善将为合规企业的健康持续发展创造较好的条件","url":"https://stock-news.laohu8.com/highlight/detail?id=2614814816","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614814816?lang=zh_cn&edition=full","pubTime":"2026-02-28 17:51","pubTimestamp":1772272271,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)02月28日在投资者关系平台上答复投资者关心的问题。投资者提问：2026年3月份开始，保健食品线上推广销售将迎来更严厉监管，公司主要收入为线下销售，是否意味着公司终于迎来大展身手的时候？建议公司积极开展相关工作，推进公司业绩增长，为公司和投资者创造更美好的未来！汤臣倍健回复：投资者您好！行业相关法规的陆续完善将为合规企业的健康持续发展创造较好的条件。感谢您的建议。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022800011767.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0146","BK0042","BK0107","BK0114","BK0226","300146"],"gpt_icon":0},{"id":"2614981687","title":"汤臣倍健：公司已递交轻络素相关的新功能申报及产品注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2614981687","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614981687?lang=zh_cn&edition=full","pubTime":"2026-02-28 17:51","pubTimestamp":1772272270,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)02月28日在投资者关系平台上答复投资者关心的问题。投资者提问：公司的产品轻络素和pcc1目前进展到哪一步了，有没有持续跟踪？汤臣倍健回复：投资者您好！公司已递交轻络素相关的新功能申报及产品注册申请，目前尚在审批中；相关产品进展请以公司官方发布的信息为准。感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022800011766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0107","BK0146","BK0042","300146","BK0226","BK0028","BK0114"],"gpt_icon":0},{"id":"2611490291","title":"汤臣倍健新提交“未公开”等2件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2611490291","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611490291?lang=zh_cn&edition=full","pubTime":"2026-02-15 06:09","pubTimestamp":1771106965,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示，近日汤臣倍健股份有限公司新提交“未公开”等2件商标注册申请。商标申请详情如下：今年以来汤臣倍健股份有限公司新申请注册商标11件，截止目前公司共持有注册商标7918件，另有412件商标尚在注册申请中。通过天眼查大数据分析，汤臣倍健股份有限公司共对外投资了39家企业，参与招投标项目56次；财产线索方面有商标信息5687条，专利信息711条，著作权信息57条；此外企业还拥有行政许可864个。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021500000923.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0114","300146","BK0146","BK0226","BK0107","BK0028"],"gpt_icon":0},{"id":"2610493316","title":"汤臣倍健：以消费者健康需求为核心","url":"https://stock-news.laohu8.com/highlight/detail?id=2610493316","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610493316?lang=zh_cn&edition=full","pubTime":"2026-02-11 18:06","pubTimestamp":1770804365,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)02月11日在投资者关系平台上答复投资者关心的问题。投资者提问：近年来各种网红益生菌、保健产品在各大平台销售火爆，价格战打的火热。这种行业现状公司是如何应对的呢？汤臣倍健回复：投资者您好！公司始终以消费者健康需求为核心，通过科研创新推动产品升级与成果转化，适应渠道特性持续优化产品组合，为消费者提供多样化的产品选择；同时持续提升精细化运营能力，夯实核心竞争力，以适应行业竞争格局的长期变化。感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021100028927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300146","BK0042","BK0226","BK0107","BK0146","BK0028","BK0114"],"gpt_icon":0},{"id":"2610617444","title":"汤臣倍健：公司坚持实施积极、持续、稳定的分红政策","url":"https://stock-news.laohu8.com/highlight/detail?id=2610617444","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610617444?lang=zh_cn&edition=full","pubTime":"2026-02-10 16:48","pubTimestamp":1770713286,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)02月10日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司是准备开始提升市值管理，减少分红了么？汤臣倍健回复：投资者您好！公司持续关注市值表现，始终聚焦主业，致力于实现可持续、有质量发展，长期创造价值回报广大投资者。公司坚持实施积极、持续、稳定的分红政策，上市以来累计现金分红金额占累计归属于上市公司股东净利润的比例超过70%。2025年度分红计划请以公司公告为准。感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000026497.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0107","BK0042","BK0226","BK0028","BK0114","300146","BK0146"],"gpt_icon":0},{"id":"2609530646","title":"汤臣倍健：公司产品均按照国家批准的保健功能进行合规标识与宣传","url":"https://stock-news.laohu8.com/highlight/detail?id=2609530646","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609530646?lang=zh_cn&edition=full","pubTime":"2026-02-06 11:33","pubTimestamp":1770348797,"startTime":"0","endTime":"0","summary":"根据国家市场监督管理总局的规定，目前允许保健食品声称的保健功能共24项，其中包括“有助于抗氧化”“有助于增强免疫力”等功能，尚未将“抗衰老”或“抵抗病毒”单独列为可声称的保健功能。公司产品目前均按照国家批准的保健功能进行合规标识与宣传。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600015918.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300146","BK0114","BK0226","BK0028","BK0042","BK0146","BK0107"],"gpt_icon":0},{"id":"2606633215","title":"汤臣倍健：公司将持续加强客服人员产品培训与考核","url":"https://stock-news.laohu8.com/highlight/detail?id=2606633215","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606633215?lang=zh_cn&edition=full","pubTime":"2026-01-26 17:24","pubTimestamp":1769419450,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健01月26日在投资者关系平台上答复投资者关心的问题。雪球平台用户“汤汤讲解员”非公司官方账号。公司将持续加强客服人员产品培训与考核。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600022721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0107","300146","BK0042","BK0146","BK0028","BK0226"],"gpt_icon":0},{"id":"2606218613","title":"汤臣倍健：截至2025年三季度末，孙惠刚已退出前十大股东","url":"https://stock-news.laohu8.com/highlight/detail?id=2606218613","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606218613?lang=zh_cn&edition=full","pubTime":"2026-01-26 16:24","pubTimestamp":1769415850,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)01月26日在投资者关系平台上答复投资者关心的问题。投资者提问：我问一下前十大股东，孙惠刚现在持股多少？为什么十大股东里没有孙惠刚了？汤臣倍健回复：投资者您好！截至2025年三季度末，孙惠刚已退出前十大股东，具体情况可查阅公司2025年第三季度报告。感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600016820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0107","BK0114","300146","BK0042","BK0028","BK0146","BK0226"],"gpt_icon":0},{"id":"2606426587","title":"股市必读：汤臣倍健（300146）1月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2606426587","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606426587?lang=zh_cn&edition=full","pubTime":"2026-01-26 02:50","pubTimestamp":1769367016,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，汤臣倍健报收于12.64元，上涨1.12%，换手率1.7%，成交量19.1万手，成交额2.4亿元。董秘最新回复投资者： 我是股东，同意前面投资者建议，公司应该生产功能性饮料，受众更广泛，审批周期也短，可以拓宽价值链，更好发挥公司品牌、技术、生产等协同优势。请董秘将此建议郑重提交董事长。当日关注点来自交易信息汇总：1月23日主力资金净流出461.39万元，游资资金净流出706.75万元，散户资金净流入1168.14万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600001244.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","BK0114","300146","BK0107","BK0042","BK0146","BK0028"],"gpt_icon":0},{"id":"2604588771","title":"股市必读：汤臣倍健（300146）1月19日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2604588771","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604588771?lang=zh_cn&edition=full","pubTime":"2026-01-20 02:39","pubTimestamp":1768847948,"startTime":"0","endTime":"0","summary":"截至2026年1月19日收盘，汤臣倍健报收于12.35元，上涨1.15%，换手率1.2%，成交量13.43万手，成交额1.65亿元。董秘最新回复投资者： 董秘你好！公司本来就是做保健食品的这样有损公司形象及口啤。从细微小事上做到维护品牌形不伤害消费者。提高消费者对品牌的信任度和忠诚度。上述情况已反馈至业务部门。当日关注点来自交易信息汇总：1月19日主力资金净流入284.57万元，显示主力对汤臣倍健股票短期态度偏积极。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000001004.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","BK0114","300146","BK0107","BK0042","BK0146","BK0028"],"gpt_icon":0},{"id":"2603607788","title":"汤臣倍健：已着手建立企业级AI智能体开发平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2603607788","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603607788?lang=zh_cn&edition=full","pubTime":"2026-01-15 20:51","pubTimestamp":1768481503,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)01月14日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司在那些方面应用了AI技术？汤臣倍健回复：投资者您好！公司积极探索AI赋能管理运营的路径及模式，已着手建立企业级AI智能体开发平台，发掘并稳步推进其在业务运营、研发创新、客户服务、管理提效、数据分析等多个场景应用。感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500038784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0107","BK0146","BK0226","300146","159819","BK0114","BK0042"],"gpt_icon":0},{"id":"2603369128","title":"汤臣倍健站在转型十字路口：传统模式承压与内部增长挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=2603369128","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603369128?lang=zh_cn&edition=full","pubTime":"2026-01-14 17:42","pubTimestamp":1768383720,"startTime":"0","endTime":"0","summary":"　　近年来，随着消费习惯的快速变迁和行业格局的演变，国内膳食营养补充剂行业的竞争态势已截然不同。作为行业龙头，汤臣倍健在坚守与转型之间努力寻找平衡。　　公司正尝试通过调整资源投放、优化渠道策略来应对当前的挑战。在投资者交流中，汤臣倍健也提到功能食品和海外品牌的部分产品采取了委托加工模式。　　汤臣倍健站在转型的十字路口，其过往依赖药店渠道和经销商网络的增长逻辑正面临考验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-01-14/doc-inhhhnwt4012170.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0107","BK0146","BK0042","300146","BK0226","BK0028","BK0114"],"gpt_icon":0},{"id":"2603540355","title":"股市必读：汤臣倍健（300146）1月12日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2603540355","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603540355?lang=zh_cn&edition=full","pubTime":"2026-01-13 01:44","pubTimestamp":1768239852,"startTime":"0","endTime":"0","summary":"截至2026年1月12日收盘，汤臣倍健报收于12.48元，上涨1.63%，换手率2.06%，成交量23.1万手，成交额2.87亿元。董秘最新回复投资者： 董秘您好，上海凡迪基因科技有限公司是一家专注于基因检测服务的高新技术企业，其核心业务聚焦于临床和健康领域的基因检测，与贵公司有着紧密的合作关系。公司已于2022年将上述股权全部处置，目前未持有上海凡迪股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300001452.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300146","BK0114","BK0226","BK0028","BK0042","BK0146","BK0107"],"gpt_icon":0},{"id":"2601480054","title":"股市必读：汤臣倍健（300146）1月7日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2601480054","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601480054?lang=zh_cn&edition=full","pubTime":"2026-01-08 01:04","pubTimestamp":1767805453,"startTime":"0","endTime":"0","summary":"截至2026年1月7日收盘，汤臣倍健报收于12.15元，下跌1.7%，换手率1.46%，成交量16.32万手，成交额2.0亿元。董秘最新回复投资者： 您好！贵司CEO林志成在央视微对话中说将很快落地能从源头靶向清除衰老细胞的抗衰新物质PCC1的产品，能给更多相关产品的介绍吗？现在落地进度到哪一步了？具体请以公司正式发布的产品上市信息为准。交易信息汇总资金流向1月7日主力资金净流出2594.09万元；游资资金净流入2102.07万元；散户资金净流入492.02万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800000582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","BK0114","300146","BK0107","BK0042","BK0146","BK0028"],"gpt_icon":0},{"id":"2593141732","title":"股市必读：汤臣倍健（300146）12月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2593141732","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593141732?lang=zh_cn&edition=full","pubTime":"2025-12-24 02:33","pubTimestamp":1766514790,"startTime":"0","endTime":"0","summary":"截至2025年12月23日收盘，汤臣倍健报收于12.02元，下跌1.15%，换手率1.16%，成交量12.98万手，成交额1.57亿元。董秘最新回复投资者： 尊敬的董秘，您好！2024年年报，短期借款激增至15.43亿元，年报显示是“已贴现未到期商业汇票”，请问这是质押的应收账款吗？上述主要系公司基于整体资金安排进行票据贴现业务所致，公司无应收账款质押情形。当日关注点来自交易信息汇总：12月23日主力资金净流出1099.32万元，散户资金净流入1564.95万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400001023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300146","BK0028","BK0226","BK0146","BK0114","BK0107","BK0042"],"gpt_icon":0},{"id":"2593462320","title":"汤臣倍健：公司无应收账款质押情形","url":"https://stock-news.laohu8.com/highlight/detail?id=2593462320","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593462320?lang=zh_cn&edition=full","pubTime":"2025-12-23 15:06","pubTimestamp":1766473579,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)12月23日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，您好！2024年年报，短期借款激增至15.43亿元，年报显示是“已贴现未到期商业汇票”，请问这是质押的应收账款吗？如果是，为什么“应收账款”科目仅有1.65亿？是遗漏了吗？激增这么多借款的原因是什么？谢谢！汤臣倍健回复：投资者您好！上述主要系公司基于整体资金安排进行票据贴现业务所致，公司无应收账款质押情形。感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300018874.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0107","BK0146","BK0226","300146","BK0114","BK0042"],"gpt_icon":0},{"id":"2592920997","title":"汤臣倍健：坚持差异化战略打造产品科技力","url":"https://stock-news.laohu8.com/highlight/detail?id=2592920997","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592920997?lang=zh_cn&edition=full","pubTime":"2025-12-18 15:06","pubTimestamp":1766041587,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健12月18日在投资者关系平台上答复投资者关心的问题。差异化是用户需求而其它企业没能满足的东西，而非仅仅是与众不同。没有差异化产品的商业模式基本不是好的商业模式。公司坚持执行差异化战略，在全球范围内科学甄选优质原料，深入开展自有知识产权原料、新功能和重功能创新产品开发，持续打造产品科技力和差异化竞争优势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800017388.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","BK0114","300146","BK0107","BK0042","BK0146","BK0028"],"gpt_icon":0},{"id":"2590037861","title":"【机构调研记录】长盛基金调研汤臣倍健、博苑股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2590037861","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590037861?lang=zh_cn&edition=full","pubTime":"2025-12-10 08:05","pubTimestamp":1765325146,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及12月9日披露的机构调研信息，长盛基金近期对2家上市公司进行了调研，相关名单如下：1）汤臣倍健 调研纪要：公司聚焦主业，推动长期有质量发展。第四季度净利润受费用投放、奖金计提等影响。2）博苑股份 调研纪要：公司精细化学品主要包括碘化物、发光材料、六甲基二硅氮烷和贵金属催化剂，其中碘化物为营收核心。2025年12月11日将解除限售19,630,000股，目前未收到股东减持计划通知。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000004481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0107","BK0114","301617","BK0229","BK0146","BK0042","BK0028","BK0226","300146"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772496320504,"stockEarnings":[{"period":"1week","weight":-0.0231},{"period":"1month","weight":-0.0288},{"period":"3month","weight":-0.0231},{"period":"6month","weight":-0.0008},{"period":"1year","weight":0.0518},{"period":"ytd","weight":-0.0158}],"compareEarnings":[{"period":"1week","weight":0.0246},{"period":"1month","weight":0.0157},{"period":"3month","weight":0.0731},{"period":"6month","weight":0.0968},{"period":"1year","weight":0.2595},{"period":"ytd","weight":0.0539}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"汤臣倍健股份有限公司","boardCode":"AI0014","boardName":"食品制造业","stockholders":"71105人(较上一季度减少0.14%)","perCapita":"15762股","listingDate":"2010-12-15","address":"广东省珠海市金湾区三灶科技工业园星汉路19号","registeredCapital":"169167万元","survey":"　　汤臣倍健股份有限公司的主营业务是膳食营养补充剂的生产销售。公司的主要产品是片剂、粉剂、胶囊、其他。截至报告期末，公司获得134项原料及配方等发明专利。","listedPrice":110},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"汤臣倍健(300146)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供汤臣倍健(300146)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"汤臣倍健,300146,汤臣倍健股票,汤臣倍健股票老虎,汤臣倍健股票老虎国际,汤臣倍健行情,汤臣倍健股票行情,汤臣倍健股价,汤臣倍健股市,汤臣倍健股票价格,汤臣倍健股票交易,汤臣倍健股票购买,汤臣倍健股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"汤臣倍健(300146)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供汤臣倍健(300146)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}